Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)

National Institutes of Health
Tipo

Research/project funding

Posted on

Funding Opportunity RFA-AI-24-080 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support the development of improved products for treating Botulinum Neurotoxin (BoNT) intoxication. Development of products that can reverse BoNT intoxication are highly encouraged. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the R33 phase will depend on the successful completion of specific milestones during the R61 phase.

More Information

Tipo

Research/project funding

Posted on

, Estados Unidos